证券代码：300841 证券简称：康华生物 公告编号：2026-007 成都康华生物制品股份有限公司 关于为公司及董事、高级管理人员购买责任保险的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏, 并就其保证承担个别和连带的责任。 成都康华生物制品股份有限公司（以下简称"公司"）于2026年1月28日召 开第三届董事会第十三次会议，审议了《关于为公司及董事、高级管理人员购买 责任保险的议案》。为进一步完善公司风险管理体系，降低公司治理和运营风险， 保障公司利益，促进公司董事及高级管理人员充分行使权利、履行职责，根据《中 华人民共和国公司法》《上市公司治理准则》等有关规定，公司拟为公司及全体 董事、高级管理人员以及相关责任人员购买责任保险。现将具体情况公告如下： 一、责任保险具体方案 1、投保人：成都康华生物制品股份有限公司 2、被保险人：公司及全体董事、高级管理人员以及相关责任人员（具体以 最终签订的保险合同约定为准） 为提高决策效率，公司董事会提请股东会授权董事会并同意由董事会授权公 司管理层在上述责任保险方案范围内办理责任保险业务相关事宜（包括但不限于 ...

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Market Overview - The A-share market exhibited a fluctuating and differentiated pattern last week, with major indices showing mixed performance and active rotation among hot sectors [1][7] - Institutions generally hold an optimistic outlook, believing the market is likely to trend upward [1][7] - As of January 25, over 950 companies have disclosed their 2025 earnings forecasts, with around 40% of these companies showing positive performance [1][7] Semiconductor Industry - The semiconductor industry, particularly companies related to artificial intelligence, data center construction, and domestic substitution, is expected to see strong earnings growth in 2025 [1][8] - Notable companies include: - Zhongwei Semiconductor expects revenue of approximately 1.122 billion yuan, a year-on-year increase of about 23%, and a net profit of 284 million yuan, up approximately 107% [8] - Juchip Technology anticipates revenue of 922 million yuan, a 41.44% increase, and a net profit of 204 million yuan, up 91.40% [2] - Baiwei Storage forecasts revenue between 10 billion to 12 billion yuan, a growth of 49.36% to 79.23%, and a net profit of 850 million to 1 billion yuan, a staggering increase of 427.19% to 520.22% [3][9] Pharmaceutical Industry - The pharmaceutical sector is experiencing a "polarized" performance, with over 60 companies disclosing earnings forecasts, about half of which are positive [1][9] - Key performers include: - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan, a year-on-year increase of 214% to 371% [10] - Shanghai Yizhong anticipates a net profit of 6 million to 7 million yuan, a growth of 760.18% to 903.54% [10] - However, companies like Zhifei Biological are projected to incur significant losses, with an expected net loss of 10.7 billion to 13.7 billion yuan [10][5] Banking Sector - As of January 25, eight listed banks have released earnings reports, with all showing year-on-year growth in net profit [5][11] - Key statistics include: - China Merchants Bank's total assets surpassing 13 trillion yuan, and Industrial Bank exceeding 11 trillion yuan [11] - The highest net profit growth among these banks is from Hangzhou Bank at 12.05%, followed by Shanghai Pudong Development Bank at 10.52% [11] - The growth drivers for banks include improved cost of liabilities and rapid growth in intermediary business income, with Ningbo Bank's net income from fees and commissions increasing by 30.72% [12]

Core Viewpoint - The performance of human rabies vaccine companies is declining despite an increase in rabies cases in China, with major manufacturers like Chengda Biological and Kanghua Biological forecasting significant drops in net profits for 2025 [1][2]. Company Performance - Chengda Biological expects a net profit of 123 million to 139 million yuan for 2025, representing a year-on-year decrease of 59.34% to 63.98% [1]. - Kanghua Biological anticipates a net profit decline of 41.55% to 52.09% for the same period [1]. Industry Context - Rabies is a highly fatal disease with a near 100% mortality rate once symptoms appear, making vaccination crucial for control [2]. - The human rabies vaccine market in China is experiencing a contraction due to regulatory changes and intensified market competition [2][4]. - The number of manufacturers in the human rabies vaccine sector has increased, leading to heightened competition and market share erosion for established players like Chengda Biological [4][5]. Regulatory Changes - The Chinese CDC's 2023 guidelines have revised vaccination protocols, reducing the number of doses required for certain populations, which is expected to decrease overall vaccine usage [5][6]. - The new guidelines state that individuals exposed to rabies after three months of full vaccination only need two doses of the vaccine, compared to previous requirements that could involve more doses [6]. Market Dynamics - The domestic market for human rabies vaccines has entered a phase of oversupply since 2021, with 12 companies receiving approval for rabies vaccines by 2024 [5]. - Approximately 40 million people in China are exposed to rabies annually, but the vaccination rate for this group is only about 35%, indicating potential for market growth despite current challenges [2].

Core Viewpoint - Kanghua Biotech (300841.SZ) has officially launched Phase I clinical trials for its recombinant hexavalent norovirus vaccine (Pichia pastoris) in mainland China, marking a significant step in the development of a vaccine aimed at preventing norovirus infections and the acute gastroenteritis they cause [1] Group 1: Vaccine Development - The recombinant hexavalent norovirus vaccine (Pichia pastoris) is designed to prevent norovirus infections and the resulting acute gastroenteritis [1] - Norovirus is a major pathogen responsible for acute gastroenteritis outbreaks across all age groups globally, with no approved treatment or preventive vaccine currently available [1] - The vaccine utilizes innovative genetic engineering technology based on virus-like particles (VLPs), theoretically capable of preventing over 90% of norovirus infections and related acute gastroenteritis [1]

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. has officially launched Phase I clinical trials for its recombinant hexavalent norovirus vaccine (Pichia pastoris) in mainland China, marking a significant step in addressing the lack of approved treatments or preventive vaccines for norovirus infections [1] Group 1: Vaccine Development - The recombinant hexavalent norovirus vaccine is an innovative vaccine constructed using genetic engineering technology based on virus-like particles (VLPs), theoretically capable of preventing over 90% of norovirus infections and the acute gastroenteritis they cause [1] - The Phase I clinical trial aims to evaluate the safety and immunogenicity of the vaccine in healthy individuals aged 6 weeks and older, utilizing a randomized, double-blind, placebo-controlled design [1] Group 2: Market Context - Norovirus is a major pathogen responsible for acute gastroenteritis outbreaks across all age groups, and its prevention has garnered significant attention [1] - Currently, there are no approved therapeutic drugs or preventive vaccines for norovirus globally, indicating a substantial market opportunity for Kanghua's vaccine development [1] Group 3: Future Plans - The company plans to accelerate the clinical research process for the vaccine, aiming for steady progress in its development efforts [1]

Core Viewpoint - The company has officially launched Phase I clinical trials for its recombinant hexavalent norovirus vaccine (Pichia pastoris) in mainland China, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The recombinant hexavalent norovirus vaccine is developed using genetic engineering technology based on virus-like particles (VLPs) [1] - This innovative vaccine is designed to prevent norovirus infections and the acute gastroenteritis they cause [1] - The vaccine theoretically has the potential to prevent over 90% of norovirus infections and related acute gastroenteritis [1]

证券代码：300841 证券简称：康华生物 公告编号：2026-002 重组六价诺如病毒疫苗（毕赤酵母）适用于预防诺如病毒感染及其引起的急 性肠胃炎。诺如病毒是全球范围内引起全年龄段人群急性肠胃炎流行及暴发的主 要病原体之一，目前全球范围内尚无对症治疗药物或预防疫苗产品获批上市。 公司重组六价诺如病毒疫苗（毕赤酵母）是采用基因工程技术构建的基于病 毒样颗粒（VLPs）的创新型疫苗，适用于预防诺如病毒感染及其引起的急性肠 胃炎，理论上可以预防 90%以上的诺如病毒感染及其引起的急性肠胃炎。 成都康华生物制品股份有限公司 关于重组六价诺如病毒疫苗（毕赤酵母）启动Ⅰ期 临床试验并完成首例受试者入组的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，成都康华生物制品股份有限公司（以下简称"公司"）研发的重组六 价诺如病毒疫苗（毕赤酵母）在中国大陆正式启动Ⅰ期临床试验，并完成首例受 试者入组。现将相关情况公告如下： 一、疫苗基本信息 | 名称 | 剂型 | 规格 | 注册分类 | | 临床试验分期 | | --- | --- | --- | --- | --- ...

Core Viewpoint - The A-share market saw a significant rise in vaccine stocks, driven by the outbreak of the Nipah virus in West Bengal, India, which has a high mortality rate and no available vaccine [1][2]. Group 1: Market Performance - Hualan Vaccine and Jindike both reached the daily limit of 20% increase, while Zhifei Biological rose over 15%, Kangle Health over 13%, and CanSino over 12% [1]. - Other notable increases included Watson Bio with a rise of over 10%, Kangtai Bio by nearly 7%, and Wantai Bio by almost 6% [1]. - The total market capitalization for Hualan Vaccine is 14 billion, Jindike is 3.11 billion, and Zhifei Biological is 47.7 billion [2]. Group 2: Year-to-Date Performance - Year-to-date, Hualan Vaccine has increased by 25.28%, Jindike by 24.96%, and Kangle Health by 36.15% [2]. - Zhifei Biological has a year-to-date increase of 5.67%, while Watson Bio has risen by 32.24% [2]. - Kangtai Bio's year-to-date increase stands at 16.59%, and Wantai Bio at 4.47% [2]. Group 3: Industry Context - The Nipah virus outbreak has prompted the Thai Civil Aviation Authority to implement comprehensive screening for flights from West Bengal to prevent the virus from entering Thailand [1]. - Jindike has acknowledged awareness of the Nipah virus news but stated that the company does not have related products [1].

Core Viewpoint - The A-share market saw a significant rise in vaccine stocks due to the outbreak of the Nipah virus in West Bengal, India, which has a high mortality rate and no available vaccine [1] Group 1: Market Performance - Vaccine stocks such as Hualan Biological, Gendik, and Zhifei Biological experienced substantial gains, with Gendik hitting the 20% limit up, Zhifei Biological rising over 15%, and Kangle Health increasing by over 13% [1] - Other notable increases included CanSino Biologics up by over 12%, Watson Biotech by over 10%, and Kangtai Biological by over 7% [1] Group 2: Company Specifics - Gendik acknowledged awareness of the Nipah virus news but stated that the company does not have related products [1] - The total market capitalization of leading vaccine companies includes Zhifei Biological at 477 billion, Watson Biotech at 230 billion, and CanSino Biologics at 192 billion [2]